Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Woodline Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Woodline Partners

Woodline Partners

Operating

San Francisco-based Woodline Partners LP is a private equity firm specializing in global Health Care and Technology sectors.

Founded
2018
Firm
Compare
Portfolio
Employees
Website

Investments

Cuprum Metals
Cuprum Metals
Series A

Total Raised

$19.4M

Rounds

1

Series A$19.4MJune 2026
Outlook Therapeutics
Outlook Therapeutics
Public

Total Raised

$335.3M

Rounds

13

Post Ipo Equity$65MJanuary 2024
Odyssey Therapeutics
Odyssey Therapeutics

Total Raised

$487M

Rounds

3

Series C$101MDecember 2023
Series B$168MOctober 2022
Series A$218MDecember 2021
Soleno Therapeutics
Soleno Therapeutics
Public

Total Raised

$160.5M

Rounds

4

Post Ipo Equity$129MSeptember 2023
Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Immunome
Immunome
Public

Total Raised

$218.9M

Rounds

20

Post Ipo Equity$125MJune 2023
Lyra Therapeutics
Lyra Therapeutics
Public

Total Raised

$264.1M

Rounds

11

Post Ipo Equity$50MMay 2023
ElevateBio
ElevateBio

Total Raised

$1.2B

Rounds

5

Series D$401MMay 2023
Maze Therapeutics
Maze Therapeutics

Total Raised

$381M

Rounds

3

Series Unknown$190MJanuary 2022
Arbor Biotechnologies
Arbor Biotechnologies

Total Raised

$230.6M

Rounds

2

Series B$215MNovember 2021
Cedilla Therapeutics
Cedilla Therapeutics

Total Raised

$138.8M

Rounds

3

Series B$25MOctober 2021
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals
Public

Total Raised

$448.5M

Rounds

9

Series C$135MJuly 2021
Frontier Medicines
Frontier Medicines

Total Raised

$244M

Rounds

3

Series B$88.5MJuly 2021
Series B$88.5MJuly 2019
Kriya Therapeutics
Kriya Therapeutics

Total Raised

$600.5M

Rounds

5

Series B$100MJuly 2021
Talkspace
Talkspace
Public

Total Raised

$413.7M

Rounds

14

Post Ipo Equity$300MJune 2021
NeoGenomics Laboratories
NeoGenomics Laboratories
Acquired

Total Raised

$350.5M

Rounds

4

Post Ipo Equity$200MMay 2021
Affinia Therapeutics
Affinia Therapeutics

Total Raised

$170M

Rounds

2

Series B$110MMay 2021
Patreon
Patreon

Total Raised

$413.3M

Rounds

10

Series F$155MApril 2021
Vividion Therapeutics
Vividion Therapeutics
Acquired

Total Raised

$371.5M

Rounds

5

Series C$135MFebruary 2021
Scorpion Therapeutics
Scorpion Therapeutics

Total Raised

$270M

Rounds

2

Series B$162MJanuary 2021
Kronos Bio
Kronos Bio
Public

Total Raised

$278M

Rounds

4

Private Equity$155MAugust 2020